Clinical Trial Update: Safety and Efficacy Study of SOM230 s.c. in Cluster Headache [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of SOM230 s.c. in cluster headache was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cluster Headache

Drugs mentioned

• SOM230 (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cluster Headache - Episodic and Chronic | Phase 2 | Status: TERMINATED | Results posted: 2020-01-13